Virobay, an early-stage biotech developing a drug platform for pain, Crohn's disease and psoriasis, filed on Wednesday with the SEC to raise up to $50 million in an initial public offering. The company's drug development platform is based on inhibiting cysteine...read more
ChemoCentryx, which is developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo, will see its quiet period end on 3/19/12. On 2/8/12, the company raised $45.0 million by offering 4.5 million shares at $10.00, below the range of $14.00 to...read more
This week saw 8 IPOs completed, the most deals priced since the week of December 12th (which itself was the busiest week of 2011) and the returns left investors happy. Despite significant pricing pressure (only two managed to price at the midpoint; the rest were...read more
ChemoCentryx, a biotech developing novel drugs for Crohn's disease and rheumatoid arthritis, raised $45 million by offering 4.5 million shares at $10, below the range of $14 to $16. The company had originally planned to sell 4 million shares, resulting in a...read more
TPG-backed biotech Virobay files for a $50 million IPO
Virobay, an early-stage biotech developing a drug platform for pain, Crohn's disease and psoriasis, filed on Wednesday with the SEC to raise up to $50 million in an initial public offering. The company's drug development platform is based on inhibiting cysteine...read more
ChemoCentryx quiet period ends March 19
ChemoCentryx, which is developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo, will see its quiet period end on 3/19/12. On 2/8/12, the company raised $45.0 million by offering 4.5 million shares at $10.00, below the range of $14.00 to...read more
Caesars stands out in a busy pricing week with strong returns
This week saw 8 IPOs completed, the most deals priced since the week of December 12th (which itself was the busiest week of 2011) and the returns left investors happy. Despite significant pricing pressure (only two managed to price at the midpoint; the rest were...read more
ChemoCentryx prices downsized IPO at $10, below the range
ChemoCentryx, a biotech developing novel drugs for Crohn's disease and rheumatoid arthritis, raised $45 million by offering 4.5 million shares at $10, below the range of $14 to $16. The company had originally planned to sell 4 million shares, resulting in a...read more